Biohit Oyj — Director's Dealing 2018

Mar 5, 2018

Disclosure 359167

Biohit Oyj - Managers' transactions

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions, March 5, 2018 at 2:00 pm local time (EEST)

Biohit Oyj has received the following notification.

Biohit Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Ilari Patrakka

Position: Other senior manager

Issuer: Biohit Oyj

LEI: 74370089ATTSNBXJVT29

Notification type: INITIAL NOTIFICATION

Reference number: 74370089ATTSNBXJVT29_20180301113245_5

____________________________________________

Transaction date: 2018-02-28

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009005482

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 200 Unit price: 4.48 EUR

(2): Volume: 300 Unit price: 4.48 EUR

(3): Volume: 241 Unit price: 4.48 EUR

(4): Volume: 97 Unit price: 4.5 EUR

(5): Volume: 22 Unit price: 4.5 EUR

(6): Volume: 2,303 Unit price: 4.5 EUR

(7): Volume: 97 Unit price: 4.5 EUR

(8): Volume: 129 Unit price: 4.5 EUR

(9): Volume: 97 Unit price: 4.5 EUR

(10): Volume: 147 Unit price: 4.5 EUR

(11): Volume: 211 Unit price: 4.5 EUR

(12): Volume: 3 Unit price: 4.5 EUR

(13): Volume: 221 Unit price: 4.5 EUR

(14): Volume: 241 Unit price: 4.5 EUR

(15): Volume: 145 Unit price: 4.5 EUR

(16): Volume: 1,100 Unit price: 4.54 EUR

(17): Volume: 500 Unit price: 4.5 EUR

(18): Volume: 2,000 Unit price: 4.5 EUR

(19): Volume: 250 Unit price: 4.5 EUR

(20): Volume: 77 Unit price: 4.56 EUR

(21): Volume: 109 Unit price: 4.57 EUR

(22): Volume: 310 Unit price: 4.55 EUR

(23): Volume: 800 Unit price: 4.55 EUR

Aggregated transactions

(23): Volume: 9,600 Volume weighted average price: 4.5101 EUR

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi

www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com